Empowering the Fight for Health and Well-being as a Human Right

Our Success in Numbers

Play Video

Pioneering Healthcare Solutions Globally

At Citadel Pharmaceuticals and Biologicals, we are committed to continuously innovating, striving to discover solutions that enhance the quality of life for everyone, both today and tomorrow.

Fulfilling unmet patient needs

We tailor our healthcare solutions in response to the most demanding unmet medical needs. Our therapeutic areas of focus include oncology, neuroscience, respiratory, cardiometabolic medicine, anti-infectives, ophthalmology, bone health and pain management, hepatology, slimming and wellbeing, sexual and reproductive health.

Bridging the globe through the catalytic power of partnerships

We believe in the sustainable impact of collaborations. With a track record of successful alliances, we play a crucial role in delivering life-saving treatments for pressing health challenges such as HIV, HBV, HCV, COVID-19, and diabetes. And today we are pioneering the tech. transfer and local manufacturing of diverse biological treatments for sustainable accessibility in low- to middle-income countries.

Innovating for a better quality of life

With a heritage that spans a century, we have in-house expertise that powers both manufacturing and research capabilities. Our three, globally certified, manufacturing facilities are supported by 2 research centers that ensure we not only create cutting-edge and innovative solutions but also have the scale to produce them for the masses.

Research and development is at the heart of everything we do.

We know that investing in innovation is investing in our future.

Highlights

News and Media

Citadel Pharma and Vodafone Business Announce Groundbreaking Partnership to Deliver Innovative Digital Health Solutions

28 July, 2024

News and Media

Citadel Pharma Inaugurates its New State-of-the-Art Dietary Supplement Facility “Limitless Naturals”

30 July, 2024

News and Media

Lilly and Citadel Pharma collaborate to expand access to baricitinib in low- to middle-income countries

04 Sep, 2024